Table 1.
Use of any macrolide and subtypes in mothers and infants during pregnancy and up to 120 days after birth in a Danish cohort of 999 378 singletons, 1996 to 2011
| Drugs ever used | No (% among ever users of any macrolide)* | ||
|---|---|---|---|
| Maternal use during pregnancy | Maternal use 0-120 days after birth | Use in infants 0-120 days after birth | |
| Any macrolide | 30 091 (100) | 21 557 (100) | 6591 (100) |
| Erythromycin | 25 240 (83.9) | 11 146 (51.7) | 5372 (81.5) |
| Roxithromycin | 4193 (13.9) | 6614 (30.7) | 2 (0.03) |
| Azithromycin | 6757 (22.5) | 3947 (18.3) | 425 (6.4) |
| Clarithromycin | 930 (3.1) | 1030 (4.8) | 855 (13.0) |
| Spiramycin | 193 (0.6) | 1 (<0.01) | — |
| >1 macrolide subtype | 1386 (4.6) | 1151 (5.3) | 63 (0.96) |
*Since a cohort member could have used more than one macrolide subtype, percentages for individual subtypes add up to more than 100%.